Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...
Asal Shirazi, Founder of ASA Foundation, shares insights into what drives inflammatory responses, including the role of ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...
Immunotherapy has emerged in recent years as a new cancer treatment that is gentler than traditional chemotherapy and causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback